About Us

Innovative Therapies for Complex Diseases
Repligen's Development Pipeline

Repligen is developing a pipeline of innovative products and therapies with the potential to make a significant impact in the lives of patients suffering from diseases with limited treatment options. The company's diverse pipeline includes the following development programs:

  • SecreFlo(TM), synthetic human secretin, positive Phase 3 study completed to improve magnetic resonance imaging of the pancreas
  • SecreFlo(TM), synthetic human secretin, investigator led pilot studies to improve pancreatic cancer detection
  • RG3039, promoters of SMN2 gene expression, entering Phase 1 for spinal muscular atrophy
  • RG2833, HDAC (Class 1) inhibitors, in preclinical development for Friedreich's ataxia

RG1068 Pancreatic Imaging RG1068 Pancreatic Cancer RG3039 Spinal Muscular Atrophy RG2833 Friedrich's Ataxia Bioprocessing Business - Biological Purification Orencia Royalties - Rheumatoid Arthritis